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Background: Although familial Mediterranean fever (FMF) was originally defined as an autosomal recessive
disorder, approximately 10–20% of FMF patients do not carry any FMF gene (MEFV) mutations. Fine phenotype
characterization may facilitate the elucidation of the genetic background of the so called “FMF without MEFV
mutations”. In this study we clinically and demographically characterize this subset.
Methods: MEFV mutation-negative FMF and control patients were recruited randomly from a cohort followed in a
dedicated FMF clinic. The control subjects comprised 2 groups: 1. typical population of FMF, consisting of genetically
heterogeneous patients manifesting the classical spectrum of FMF phenotype and 2. a severe phenotype of FMF,
consisting of FMF patients homozygous for the p.M694V mutation.
Results: Forty-seven genetic-negative, 60 genetically heterogeneous and 57 p.M694V homozygous FMF patients were
enrolled to the study. MEFV-mutation negative FMF patients showed a phenotype closely resembling that of the other
2 populations. It differed however from the p.M694V homozygous subset by its milder severity (using Mor et al. scoring
method), as determined by the lower proportion of patients with chest and erysipelas like attacks, lower frequency of
some of the chronic manifestations, lower colchicine dose and older age of disease onset.
Conclusions: MEFV mutation-negative FMF by virtue of its classical FMF phenotype is probably associated with a genetic
defect upstream or downstream to MEFV related metabolic pathway.
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Familial Mediterranean fever (FMF) is an autosomal, re-
cessively inherited autoinflammatory disease, associated
with the MEditerranean FeVer gene (MEFV) and charac-
terized by recurrent episodes of fever and serositis,
mostly peritonitis, but also pleuritis, pericarditis and
synovitis [1,2]. The MEFV gene product is pyrin, a pro-
tein thought to play an important role in the regulation
of interleukin 1β (IL1β) and thereby of inflammation [3].
To date, according to Infevers, a database dedicated to
auto-inflammatory mutations, more than 100 sequence
variations have been identified in the MEFV, mostly due
to single nucleotide substitutions [4]. Only a small num-
ber of these variants are unambiguously pathogenic and* Correspondence: Ilan.Benzvi@sheba.health.gov.il
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unless otherwise stated.associated with the FMF phenotype. The most common
pathogenic mutations worldwide are the p.M694V,
M694I, M680I and V726A.
Although FMF was originally defined as an autosomal
recessive disorder, approximately 25% of the patients
carry only 1 MEFV mutation [5], and 10–20% carry no
mutations at all [6]. Molecular analysis performed in
previous studies confirmed the lack of other rare muta-
tions in these patients [7,8]. Thus, the diagnosis of FMF
still relies on clinical criteria [9], rather than genetic test-
ing. Genetic analysis, if yielding, may help at most in
atypical presentations [10].
The genetic flaw in the so called “FMF without MEFV
mutations” is still elusive. The many theories exist may
be condensed into two. One possible explanation is that
this entity is associated with yet unknown upstream or
downstream genetic defects in a component of the same
metabolic pathway of pyrin. By this option genetic nega-
tive FMF patients are expected to bear a phenotypel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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other possible explanation is that this subset of FMF is
actually comprised of other autoinflammatory disorders,
in which a thoroughly and meticulously characterized
phenotype is expected to diverge from that of MEFV
mutated FMF, even if initially appeared to agree with the
clinical criteria of FMF. Thus, characterizing the pheno-
type of genetically “unaffected” FMF is essential for the
understanding of the possible underlying genetic back-
ground of this entity.
Although mutation-negative FMF is part of many ran-
domly studied cohorts of FMF patients [10-15], an exten-
sive demographic and clinical characterization of this
subset of FMF has never been the primary end point or the
main focus of previous studies. The purpose of the current
analysis is to thoroughly investigate this branch of FMF.
Methods
All study and control patients, participating in the study
were recruited from a cohort of FMF patients, coming
to their regular visit, during 2012, at the Israeli national
center for FMF in Sheba Medical Center, Tel-Hashomer
and fulfilling the clinical criteria for diagnosis of FMF
[9]. The patients and controls who consented, were re-
cruited by one of us (CH), once monthly, at different
weekdays and from different conducting physicians (the
remaining authors), to increase random enrollment (sev-
eral patient stocks) and uniformity of data collection
(one compiler). Consecutive patients were enrolled suc-
cessively, according to the order of arrival and divided
into 3 groups, as follows:
Study group: The study group consisted of MEFV
mutation-negative FMF patients, identified as such ac-
cording to their files. Patients were considered MEFV
mutation negative, if underwent exon 10 (the most af-
fected exon) sequencing and p.E148Q mutation ana-
lysis. This screening includes the 5 most common
MEFV mutations in Israel (p.M694V, p.M694I, p.
M680I, p.V726A and p.E148Q), and most MEFV rare
mutations.
Control groups: The control subjects comprised 2 FMF
patient groups:
1. Typical FMF population, consisting of genetically
heterogeneous patients, with one or 2 mutations,
excluding those who are mutation-negative. This ref-
erence group is important because it consists of a
mixture of various phenotypes of FMF, giving the
full spectrum of clinical FMF congruous with the
definition of general FMF population.
2. Most severe phenotype of FMF, consisting of FMF
patients, homozygous for the p.M694V mutation.
This group serves as a reference for the full blown
form of FMF phenotype.The 2 control populations were chosen as they repre-
sent both, the classical and the prototype (gold standard)
phenotypes of FMF respectively. Placement of the MEFV
mutation negative cohort phenotype within the boundar-
ies outlined by the control groups increases the likeli-
hood of its true association with the disease.Data collection and parameter definition
All study and control patients who signed an informed
consent, were interviewed and their files were exten-
sively reviewed. Based on these, a questionnaire detailing
their clinical and demographic parameters was com-
pleted. Attacks of FMF were accounted for only if oc-
curred repeatedly in the same site (>3 episodes) and
were typical as described in the FMF criteria [9]. Trig-
gers for attacks were those claimed by patients, based on
their own experience, colchicine dose is the last re-
corded or declared. Intravenous colchicine was defined
by administration of 1 mg of colchicine intravenously
once weekly for at least 3 months. Proteinuria was de-
fined as more than 300 mg/24 hrs, present at the time of
the study or previously and lasting for at least 3 months,
amyloidosis was diagnosed only if biopsy proven, chronic
renal failure was defined by an elevated creatinine above
normal limit (≥1.3 mg/dL) for at least 3 months, chronic
arthritis was defined as arthritic episodes defined by a
rheumatologist, lasting at least 1 month with or without
radiographic changes. Splenomegaly was detected by phys-
ical examination or by imaging. Anemia of chronic disease
was defined as hemoglobin lower than 11 g/dl (women) or
12 g/dl (men), with no other obvious cause. The Institu-
tional review board of the Sheba Medical Center approved
the study and all subjects signed an informed consent, ac-
cording to the Declaration of Helsinki.MEFV mutation analysis
Mutation negative FMF patients were identified, based
on file notes. In patients with limited genetic data, DNA
was extracted from whole blood, using a commercial kit
(high template polymerase chain reaction preparation
kit; Roche Diagnostics, Indianapolis, IN). The p.E148Q
was studied, using polymerase chain reaction and re-
striction enzyme analyses, as described elsewhere [16].
For exon 10 sequencing, the extracted DNA was ampli-
fied, using forward and reverse primers and fluorescent
nucleotides, and sequencing was performed using ABI
PRISM 3130 Genetic Analyzer (Applied Biosystems), as
described elsewhere [17]. Of note, in our group, we re-
late to the p.E148Q variant as a mutation and not as a
single nucleotide polymorphism (SNP), although with
low penetrance, and usually mild phenotype. The MEFV
mutation analysis adopted here covers around 96% of
mutation carriage in the Israeli population [17].
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The severity of FMF was determined using a scoring
system developed by Mor et al. for FMF patients receiv-
ing colchicine [18]. Briefly, this score is comprised of
the following parameters, each equals 1 point: Simul-
taneous involvement of more than one site during
acute attack in at least 25% of attacks, more than 2 site
of attacks during the disease course, colchicine dose of
at least 2 mg/day needed to control the disease, 2 or
more attacks of pleuritis during the disease course, 2 or
more attacks of erysipelas like erythema (ELE) during
the disease course and age of disease onset younger
than 10 years old. A mild disease was defined by ≤ 1
point, moderate disease by 2 points and severe disease
by ≥ 3 points.
Statistical analysis
The Mann–Whitney U test was used for comparing non-
parametric variables between the groups. For categorical
parameters, the Fisher exact test was performed. All tests
for significance were 2 tailed. P values < 0.05 were consid-
ered statistically significant.
Results
Forty-seven MEFV genetic-negative, 60 genetically het-
erogeneous and 57 p.M694V homozygous FMF patients
were enrolled. All fulfilled the criteria for diagnosis of
FMF and all were recruited randomly and consecutively
upon arrival to the clinic. The distribution of MEFV mu-
tations in the genetically heterogeneous control group is
shown in Table 1. The rate of patients with the homozy-
gous p.M694V genotype in this group was approximately
33%, consistent with the frequency of this genotype in
the Israeli FMF population [19].
The demographic parameters are presented in Table 2.
Compared with the 2 control groups, genetic-negative
patients were significantly older at the onset of their dis-
ease and had significantly lower rate of patients with aTable 1 Distribution of various MEFV genotypes in the
genetically heterogeneous control group
Mutations Rate N (%)
p.M694V homozygous 20 (33.3%)
p.M694V heterozygous 10 (16.6%)
p.M694V compound heterozygous 16 (26.6%)




p.E148Q Homozygous 2 (3.3%)
p.E148Q Heterozygous 4 (6.6%)positive family history for FMF. The severity of the dis-
ease, calculated according to the Mor severity score, was
significantly milder in the mutation-negative patients,
compared with the 2 mutation positive patient groups
(Table 3).
Table 4 details the frequency of acute and chronic
manifestations of FMF in all groups. Altogether,
mutation-negative patients had a phenotype closely re-
sembling the phenotype of the heterogeneous mutation-
positive patients. Both groups had comparable rates of
patients with acute abdominal, chest, skin and fever
alone attacks, chronic FMF manifestations and intra-
venous colchicine treatment for refractory disease. The
mean colchicine dose needed to control the disease was
also similar between the groups. The only significant
difference was a lower frequency of joint attacks in the
genetic-negative group. None of the mutation-negative
patients had amyloidosis or renal failure. Compared
with the p.M694V homozygous patients, the mutation-
negative cohort had a significantly lower rate of patients
with acute FMF attacks in extra-abdominal sites, chronic
arthritis, chronic renal failure, elevated parameters of
chronic inflammation and the combined score of chronic
manifestations of any type. In the mutation negative patient
group, significantly lower doses of colchicine were required
to control FMF attacks, compared with their homozygous
p.M694V control peers.
Discussion
Our findings suggest that mutation-negative FMF pa-
tients display a phenotype only slightly different from
that of heterogeneous mutation positive FMF patients,
seen in a large FMF clinic in Israel. Compared to the
most severe phenotype of FMF (patients who are homo-
zygous for the p.M694V MEFV mutation), mutation-
negative patients present a quantitative difference,
expressed mainly in disease severity, which was much
milder with regard to the acute and chronic manifesta-
tions and the colchicine dose needed to control their
attacks.
MEFV mutation-negative FMF has never been in the
focus of a study. A limited description of their phenotype
however, can be occasionally encountered in a small num-
ber of studies, in which this subgroup emerged inadvert-
ently as a separate group. Padeh et al. and Ozturk et al.
described the phenotype of mutation negative pediatric pa-
tients as part of a broader genetic study of FMF [10,14].
Their findings are in line with ours in most parameters, in-
cluding predominance of abdominal attacks and lower rates
of attacks at other sites. In Ozturk’s study, also in line with
our results, MEFV mutation negative FMF patients had
lower frequency of a family history of FMF and their clin-
ical phenotype was comparable to patients who have 1 or 2
MEFV mutations. Contrary to our findings however,





P value* p.M694V homozygous
(N = 57)
P value#
Females (%) 31 (65.9%) 30 (50%) 0.117 36 (63.2%) 0.838
Age of disease onset (yrs) 19.61 ± 15.3 12.35 ± 10.36 0.011 5.76 ± 6.4 0.0001
Average diagnosis delay (yrs) 9.95 ± 11.2 6.91 ± 8 0.373 7.59 ± 9.5 0.234
Positive family history of FMF 21 (44%) 44 (73.3%) 0.003 45 (78.9%) 0.0005
*Mutation-negative vs. genetically heterogeneous controls.
#Mutation-negative vs. p.M694V homozygous.
Bold values=statistically significant.
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Ozturk’s study developed amyloidosis. This difference could
be explained by different trends in patient management be-
tween the countries and other environmental factors affect-
ing the propensity to develop amyloidosis [20].
Two methodological notes should be mentioned. First,
an extensive search for a second mutation in heterozygous
patients, including entire MEFV genomic region sequence,
did not identify one [7,8]. These findings support the ac-
curacy of our screening methodology of MEFV genetic
analysis to detect mutation negative FMF patients, and
confirm with high certainty that our cohort is a true subset
of patients with unaffected MEFV, and not a group of pa-
tients in whom MEFV mutations have been missed. Sec-
ondly, our genetically heterogeneous control group
represents the typical phenotype of FMF, as reported in
various cohorts around the world, with regard to disease
severity, manifestations of attacks, family history of FMF
and colchicine treatment [15,21,22]. The frequency of dif-
ferent MEFV mutations is also comparable to that of the
general FMF population seen in Israel [19]. Thus, it ap-
pears that the heterogenous control patients enrolled in
the present study may serve as an appropriate reference
for the “common” FMF phenotype, and used for compari-
son with the subset of interest in this study, the mutation-
negative patients.
The current study on MEFV mutation negative FMF
brings us to at least 3 comprehensions. One regards the
genetics of FMF, the second related to the phenotype of
FMF and the third to the origin of FMF without MEFV
mutations. As for the genetics, it has been already shown
that the phenotype expressed by FMF patients, carryingTable 3 Severity of FMF in MEFV mutation-negative patients
Severity score Mutation-negative (N = 47) Heterogeneo
controls (N =
Mild 27 (57.4%) 23 (38.3%)
Moderate 9 (19%) 6 (10%)
Severe 11 (23.4%) 31 (51.7%)
*Mutation-negative vs. genetically heterogeneous controls.
#Mutation-negative vs. p.M694V homozygous patients.
Bold values=statistically significant.a single MEFV mutation, is only slightly different from
that of patients with 2 MEFV mutations [21,23]. Our
study further extends this finding, showing that the same
is true for patients who carry no MEFV mutations at all.
Altogether, these findings underline the notion that
FMF, as currently perceived, is a clinical entity with
complex genetic background and it cannot be diagnosed
or excluded based on MEFV genotyping alone, giving an
extra weight for the need of a specific laboratory test to
distinguish FMF from other forms of autoinflammatory
diseases. Until such a measure is available, the merit of
stringent criteria (for instance peritonitis vs. just abdom-
inal pain or mono-arthritis of lower extremities vs. just
arthritis) is obvious and should be strived for.
Regarding the phenotype, compared with the regular
phenotype of FMF, MEFV mutation-negative patients
have a late disease onset, milder disease severity, and
lower rate of positive family history for FMF. These
characteristics put mutation-negative patients at the
milder end of the disease spectrum, together with other
distinct groups of FMF patients with milder disease se-
verity, including Ashkenazi and Iraqi Jews [24,25], pa-
tients with late onset of their disease [26] and patients
who experience a colchicine-free remission [27]. In gen-
eral, these subsets of FMF patients have lower rates of
extra-abdominal attacks, ELE, chronic arthritis, chronic
manifestations including chronic kidney disease and
amyloidosis and lower rate of elevated markers of
chronic inflammation [28]. In contrast, in different co-
horts, including ours, these patients have a relatively
high rate of typical abdominal attacks (in over 85% of
patients), just like patients with the severe form of FMFus
60)
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P value* p.M694V homozygous
(N = 57)
P value#
Average length of attack (days) 2.53 ± 1.36 2.86 ± 1.46 0.535 2.66 ± 1.5 0.857
Abdominal attacks 44 (93.6%) 53 (88.3%) 0.507 50 (87.7%) 0.509
Joint attacks 18 (38.2%) 37 (61.6%) 0.020 52 (91.3%) 0.0001
Chest attacks 18 (38.2%) 25 (41.6%) 0.842 36 (46.2%) 0.017
ELE 0 (0%) 5 (8.3%) 0.065 10 (17.5%) 0.001
Fever alone attacks 15 (31.9%) 12 (20%) 0.183 20 (35.1%) 0.835
Trigger for attacks 27 (57.4%) 34 (56.6%) 1.00 26/41 (63.4%) 0.663
Exertional leg-pain 25 (53.1%) 40 (66.6%) 0.168 47 (82.5%) 0.002
Average colchicine dose (mg/day) 1.54 ± 0.63 1.58 ± 0.53 0.727 1.9 ± 0.48 0.003
Intravenous colchicine treatment 2 (4.2%) 0 0.190 5 (8.8%) 0.452
Proteinuria above 300 mg/day 2 (4.2%) 1 (1.6%) 0.580 6 (10.5%) 0.288
Amyloidosis 0 (0%) 1 (1.6%) 1.00 5 (8.8%) 0.062
Chronic renal failure 0 (0%) 1 (1.6%) 1.00 6 (10.5%) 0.031
Kidney disease of any type£ 2 (4.2%) 1 (1.6%) 1.00 6 (10.5%) 0.288
Chronic arthritis 2 (4.2%) 2 (3.3%) 1.00 11 (19.3%) 0.034
Splenomegaly 2 (4.2%) 3 (5%) 1.00 3 (5.3%) 1.000
Anemia of chronic disease 4 (8.5%) 8/43 (18.6%) 0.217 3 (5.3%) 0.698
Chronic inflammation (SAA > 10 mg/l) 3 (6.3%) 11 (18.3%) 0.086 14/53 (26.4%) 0.008
Combined chronic disease features& 26 (55.3%) 44 (73.3%) 0.06 48 (84.2%) 0.0021
ELE- Erysipelas like erythema, SAA- Serum amyloid A.
§See definitions of parameters in the method section. * Mutation-negative vs. unselected controls. # Mutation-negative vs. p.M694V homozygous. £ Including proteinuria
above 300 mg/day, amyloidosis and chronic renal failure. & including exertional leg-pain, proteinuria above 300 mg/day, amyloidosis, chronic renal failure, chronic arthritis,
splenomegaly and anemia of chronic disease. Bold values=statistically significant.
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typical abdominal attacks dominate the clinical picture
and is the single most sensitive manifestation of FMF,
found across all patient subgroups, including those with
milder disease, as is the case for the study group in the
present work.
Finally, in relation to the root of FMF without MEFV
mutations, it is unclear, and there is a myriad of hy-
potheses, including misdiagnosis of other autoinflam-
matory disorders as FMF, epigenetic changes such as
DNA methylation or hisotne modifications of MEFV,
an interplay between genetic polymorphisms, modifier
genes and environmental factors culminating in FMF
spells, and mutations in yet unknown different genes
causing a similar disease. Another possible recent ex-
planation for MEFV mutation-negative FMF might be
somatic mosaicism, a phenomenon discovered lately, to
underly NLRP3 genetic-negative cryopyrin-associated
periodic syndrome, a genetically different autoinflam-
matory entity [29,30]. In general however, these possi-
bilities might be narrowed to 2: defects in MEFV
associated pathway or another autoinflammatory dis-
ease. Our findings showing close resemblance of muta-
tion negative FMF to mutation positive FMF supports
the former paradigm.Conclusions
In conclusion, MEFV mutation-negative FMF presents a
phenotype only slightly distinguishable from that pre-
sented by FMF patients with 1 or 2 MEFV mutations,
generally suggesting a shared metabolic pathway with
genetically positive FMF. Better understanding of the
genetics and the pathogenesis of this subset of FMF is a
target for future studies.Competing interests
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